Patent 7977091 was granted and assigned to Novartis on July, 2011 by the United States Patent and Trademark Office.
The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.